Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DRREDDY.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DRREDDY.BO and 80,000+ other tickers.
See exactly how DRREDDY.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DRREDDY.BO and 80,000+ other tickers.
Dr. Reddy's Laboratories Limited, along with its various subsidiaries, functions as a globally integrated pharmaceutical enterprise. Its operations are structured into three primary business divisions: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and 'Others'. The Global Generics segment is responsible for the production and commercialization of both prescription and over-the-counter (OTC) finished pharmaceutical products. These offerings are marketed either under proprietary brand names or as generic formulations that are therapeutically equivalent to their branded…
No recent news available.